Shanghai Henlius Biotech's (HKG:2696) application for the phase 2 clinical trial of HLX22 in two different kinds of combinations has been approved by China's National Medical Products Administration, a Wednesday bourse filing said.
The drug is being tested in combination with trastuzumab and chemotherapy or combined with trastuzumab deruxtecan for the treatment of HER2-expressing solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments